Ticker history: INDV became SUPN (Indivior Pharmaceuticals, Inc.) on .
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INDV SEC filings page.
Indivior Pharmaceuticals, Inc. (INDV) reported $1.4B in revenue over the twelve months to Sep 30, 2026, up 16.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Indivior’s 2025 accounting profit surged, but cash conversion weakened while liabilities still exceeded assets and current obligations tightened liquidity.
The earnings turnaround was not driven by stronger gross economics: revenue increased4.3% while gross margin slipped 0.3 percentage points, yet operating margin improved 17.9 percentage points. That points to improvement below gross profit—supported by R&D declining9.3% and SG&A rising only3.6% —rather than a change in the underlying product margin.
Reported net income reached
Balance-sheet flexibility remains constrained: liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Indivior Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Indivior Pharmaceuticals, Inc. scores 42/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Indivior Pharmaceuticals, Inc. scores 54/100 on it among other operating companies.
Indivior Pharmaceuticals, Inc.'s net debt of $95.0M, being $290.0M of long-term debt less $195.0M of cash, came to 0.35 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Indivior Pharmaceuticals, Inc. scores 70/100 among other operating companies measured the same way.
Indivior Pharmaceuticals, Inc. held $0.71 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 0.71. Liquidity ranks operating companies on that ratio, and Indivior Pharmaceuticals, Inc. scores 8/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Indivior Pharmaceuticals, Inc. scores 14/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Indivior Pharmaceuticals, Inc. scores 73/100 on it among other operating companies.
Indivior Pharmaceuticals, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Indivior Pharmaceuticals, Inc. used $0.13 of operating cash (-$27.0M OCF vs $210.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Indivior Pharmaceuticals, Inc. earns $6.89 in operating income for every $1 of interest expense ($262.0M vs $38.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Indivior Pharmaceuticals, Inc. generated $356.0M in revenue in Q3 2026. This represents an increase of 13.4% from the same quarter a year earlier. Against the prior quarter it is up 3.8%.
Indivior Pharmaceuticals, Inc.'s EBITDA was $181.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 293.5% from the same quarter a year earlier. Against the prior quarter it is up 11.7%.
Indivior Pharmaceuticals, Inc. reported $137.0M in net income in Q3 2026. This represents an increase of 226.2% from the same quarter a year earlier. Against the prior quarter it is up 12.3%.
Indivior Pharmaceuticals, Inc. earned $1.12 per diluted share (EPS) in Q3 2026. This represents an increase of 239.4% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.
Cash & Balance Sheet
Indivior Pharmaceuticals, Inc. generated $83.0M in free cash flow in Q3 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 62.6%.
Indivior Pharmaceuticals, Inc. held $305.0M in cash against $0 in long-term debt as of Q3 2026, with $1.3B of liabilities due within a year.
Not reported for Q3 2026.
Margins & Returns
Indivior Pharmaceuticals, Inc.'s gross margin was 85.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 12.4 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Indivior Pharmaceuticals, Inc.'s operating margin was 50.6% in Q3 2026, reflecting core business profitability. This is up 36.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.9 percentage points.
Indivior Pharmaceuticals, Inc.'s net profit margin was 38.5% in Q3 2026, showing the share of revenue converted to profit. This is up 25.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.9 percentage points.
Not reported for Q3 2026.
Capital Allocation
Indivior Pharmaceuticals, Inc. invested $5.0M in research and development in Q3 2026. This represents a decrease of 84.8% from the same quarter a year earlier. Against the prior quarter it is down 58.3%.
Indivior Pharmaceuticals, Inc. repurchased no shares in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 100.0%.
Indivior Pharmaceuticals, Inc. invested $14.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 30.0% from the same quarter a year earlier. Against the prior quarter it is up 100.0%.
INDV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $356.0M+13.4% | $343.0M+13.6% | $317.0M+19.2% | $357.0M+19.8% | $314.0M+2.3% | $302.0M+1.0% | $266.0M-6.3% | $298.0M |
| Cost of Revenue | $51.0M-38.6% | $50.0M-3.8% | $40.0M-9.1% | $67.0M+39.6% | $83.0M+25.8% | $52.0M-34.2% | $44.0M+15.8% | $48.0M |
| Gross Profit | $305.0M+32.6% | $294.0M+17.6% | $277.0M+25.3% | $293.0M+17.2% | $230.0M-4.6% | $250.0M+13.6% | $221.0M-10.2% | $250.0M |
| R&D Expenses | $5.0M-84.8% | $12.0M-42.9% | $16.0M-27.3% | $21.0M-32.3% | $33.0M+50.0% | $21.0M-19.2% | $22.0M-21.4% | $31.0M |
| SG&A Expenses | $119.0M-22.7% | $122.0M-22.8% | $124.0M-6.8% | $189.0M+8.0% | $154.0M+8.5% | $158.0M+3.9% | $133.0M-7.0% | $175.0M |
| Operating Income | $180.0M+318.6% | $160.0M+122.2% | $137.0M+107.6% | $81.0M+76.1% | $43.0M+22.9% | $72.0Mn/m | $66.0M-12.0% | $46.0M |
| EBITDA | $181.0M+293.5% | $162.0M+118.9% | $139.0M+101.4% | $83.0M+62.7% | $46.0M+17.9% | $74.0Mn/m | $69.0M-13.8% | $51.0M |
| Interest Expense | $2.0M-77.8% | $2.0M-77.8% | $7.0M-22.2% | $11.0M+22.2% | $9.0M+28.6% | $9.0M+28.6% | $9.0M+28.6% | $9.0M |
| Income Tax | $45.0Mn/m | $38.0M-13.6% | $26.0M+136.4% | -$21.0M-223.5% | -$5.0M-162.5% | $44.0Mn/m | $11.0M0.0% | $17.0M |
| Net Income | $137.0M+226.2% | $122.0M+577.8% | $89.0M+89.4% | $103.0M+390.5% | $42.0M+90.9% | $18.0Mn/m | $47.0M-23.0% | $21.0M |
| EPS (Basic) | $1.16+241.2% | $1.02+580.0% | $0.71+86.8% | $0.81+406.3% | $0.34+112.5% | $0.15n/m | $0.38-15.6% | $0.16 |
| EPS (Diluted) | $1.12+239.4% | $0.98+600.0% | $0.69+81.6% | $0.79+393.8% | $0.33+106.3% | $0.14n/m | $0.38-15.6% | $0.16 |
| Diluted Shares (Avg) | 122M-5.4% | 124M-1.6% | 129M+3.2% | N/A | 129M-3.0% | 126M-6.7% | 125M-8.8% | N/A |
INDV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B-5.9% | $1.2B-15.1% | $1.2B-12.9% | $1.2B-8.7% | $1.4B | $1.5B | $1.4B | $1.3B-25.1% |
| Current Assets | $800.0M-13.2% | $725.0M-23.8% | $667.0M-24.5% | $652.0M-21.2% | $922.0M | $951.0M | $883.0M | $827.0M-34.2% |
| Cash & Equivalents | $305.0M-31.5% | $222.0M-56.5% | $175.0M-53.0% | $195.0M-38.9% | $445.0M+54.5% | $510.0M+68.9% | $372.0M+50.0% | $319.0M+0.9% |
| Short-Term Investments | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0n/m | $0n/m | $1.0Mn/m | $1.0M-98.9% |
| Inventory | $149.0M-3.9% | $150.0M+0.7% | $152.0M-6.7% | $153.0M-8.4% | $155.0M | $149.0M | $163.0M | $167.0M+32.5% |
| Accounts Receivable | $273.0M+5.4% | $271.0M+12.9% | $273.0M+12.3% | $253.0M-0.4% | $259.0M | $240.0M | $243.0M | $254.0M0.0% |
| Long-Term Investments | $27.0M-3.6% | $27.0M0.0% | $27.0M0.0% | $28.0M+3.7% | $28.0Mn/m | $27.0Mn/m | $27.0Mn/m | $27.0M-34.1% |
| Goodwill | N/A | N/A | N/A | $2.0M0.0% | N/A | N/A | N/A | $2.0M-60.0% |
| Total Liabilities | $1.4B-14.2% | $1.4B-15.7% | $1.3B-19.2% | $1.3B-21.3% | $1.6B | $1.7B | $1.7B | $1.7B-14.9% |
| Current Liabilities | $1.3B+34.8% | $868.0M-17.8% | $779.0M-22.5% | $914.0M-1.1% | $965.0M | $1.1B | $1.0B | $924.0M-27.9% |
| Non-Current Liabilities | $91.0M-86.2% | $573.0M-12.3% | $562.0M-14.2% | $386.0M-47.0% | $658.0M | $653.0M | $655.0M | $728.0M+10.1% |
| Long-Term Debt | $0-100.0% | $487.0M+58.1% | $486.0M+56.3% | $290.0M-7.9% | $304.0M | $308.0M | $311.0M | $315.0M+32.9% |
| Total Equity | -$60.0Mn/m | -$208.0Mn/m | -$144.0Mn/m | -$98.0Mn/m | -$207.0Mn/m | -$257.0Mn/m | -$285.0Mn/m | -$337.0Mn/m |
| Retained Earnings | -$197.0Mn/m | -$334.0Mn/m | -$280.0Mn/m | -$243.0Mn/m | -$346.0M | -$388.0M | -$406.0M | -$443.0Mn/m |
INDV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $97.0Mn/m | $229.0M+44.9% | -$9.0M-112.0% | -$221.0Mn/m | -$39.0M-2050.0% | $158.0M+79.5% | $75.0Mn/m | -$17.0M |
| Depreciation & Amortization | $1.0M-66.7% | $2.0M0.0% | $2.0M-33.3% | $2.0M-60.0% | $3.0M-25.0% | $2.0M0.0% | $3.0M-40.0% | $5.0M |
| Stock-Based Compensation | $8.0M+33.3% | $11.0M+37.5% | $9.0M+50.0% | N/A | $6.0M0.0% | $8.0M+33.3% | $6.0M0.0% | N/A |
| Capital Expenditures | $14.0M-30.0% | $7.0M-58.8% | $20.0M+300.0% | $24.0M+50.0% | $20.0M+185.7% | $17.0M+325.0% | $5.0M+150.0% | $16.0M |
| Free Cash Flow | $83.0Mn/m | $222.0M+57.4% | -$29.0M-141.4% | -$245.0Mn/m | -$59.0Mn/m | $141.0M+67.9% | $70.0Mn/m | -$33.0M |
| Investing Cash Flow | -$14.0Mn/m | -$8.0Mn/m | -$19.0Mn/m | -$24.0M-400.0% | -$20.0M-157.1% | -$17.0M-1800.0% | -$5.0M-120.0% | $8.0M |
| Financing Cash Flow | $0n/m | -$173.0Mn/m | $7.0Mn/m | -$5.0M-112.5% | -$3.0Mn/m | -$5.0Mn/m | -$17.0Mn/m | $40.0M |
| Share Buybacks | $0n/m | $177.0Mn/m | $125.0M+1036.4% | $0-100.0% | $0-100.0% | $0-100.0% | $11.0M-69.4% | $50.0M |
Not reported in any period shown, so not listed: Dividends Paid.
INDV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.7%+12.4pp | 85.7%+2.9pp | 87.4%+4.3pp | 82.1%-1.8pp | 73.3%-5.2pp | 82.8%+9.2pp | 83.1%-3.5pp | 83.9% |
| Operating Margin | 50.6%+36.9pp | 46.7%+22.8pp | 43.2%+18.4pp | 22.7%+7.2pp | 13.7%+2.3pp | 23.8%+63.3pp | 24.8%-1.6pp | 15.4% |
| Net Margin | 38.5%+25.1pp | 35.6%+29.6pp | 28.1%+10.4pp | 28.8%+21.8pp | 13.4%+6.2pp | 6.0%+38.4pp | 17.7%-3.8pp | 7.0% |
| Return on Assets | 10.3%+7.3pp | 9.9%+8.7pp | 7.4%+4.0pp | 8.6%+7.0pp | 3.0% | 1.2% | 3.4% | 1.6% |
| Current Ratio | 0.61-0.3x | 0.84-0.1x | 0.860.0x | 0.71-0.2x | 0.96 | 0.90 | 0.88 | 0.90-0.1x |
| Asset Turnover | 0.270.0x | 0.28+0.1x | 0.26+0.1x | 0.30+0.1x | 0.22 | 0.21 | 0.19 | 0.23 |
| FCF Margin | 23.3%+42.1pp | 64.7%+18.0pp | -9.2%-35.5pp | -68.6%-57.6pp | -18.8%-17.2pp | 46.7%+18.6pp | 26.3%+40.0pp | -11.1% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Note: Shareholder equity is negative (-$98.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.71), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Indivior Pharmaceuticals, Inc. INDV | FY2025 | $1.2B | $210.0M | 17.0% | N/A | 44/100 |
| Collegium Pharmaceutical, Inc. COLL | FY2025 | $780.6M | $62.9M | 8.1% | $768.2M | 75/100 |
| Teva Pharmaceutical Industries Limited TEVA | FY2025 | $17.3B | $1.4B | 8.2% | $45.8B | 33/100 |
| Alkermes Inc. plc ALKS | FY2025 | $1.5B | $241.7M | 16.4% | $7.6B | 72/100 |
| BioCryst Pharmaceuticals Inc BCRX | FY2025 | $874.8M | $263.9M | 30.2% | $1.9B | 72/100 |
| ANI Pharmaceuticals, Inc. ANIP | FY2025 | $883.4M | $78.3M | 8.9% | $1.6B | 67/100 |
Where Indivior Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Indivior Pharmaceuticals, Inc. (INDV) reported $1.2B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Indivior Pharmaceuticals, Inc. (INDV) revenue grew by 4.3% year-over-year, from $1.2B to $1.2B in fiscal year 2025.
Yes, Indivior Pharmaceuticals, Inc. (INDV) reported a net income of $451.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $210.0M, with a net profit margin of 17.0%.
Indivior Pharmaceuticals, Inc. (INDV) had EBITDA of $272.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Indivior Pharmaceuticals, Inc. (INDV) had $195.0M in cash and equivalents against $290.0M in long-term debt.
Indivior Pharmaceuticals, Inc. (INDV) had a gross margin of 80.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Indivior Pharmaceuticals, Inc. (INDV) had an operating margin of 21.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Indivior Pharmaceuticals, Inc. (INDV) had a net profit margin of 17.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Indivior Pharmaceuticals, Inc. (INDV) recorded an outflow of $93.0M in free cash flow during fiscal year 2025. This represents a -1428.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Indivior Pharmaceuticals, Inc. (INDV) recorded an outflow of $27.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Indivior Pharmaceuticals, Inc. (INDV) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
Indivior Pharmaceuticals, Inc. (INDV) invested $66.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Indivior Pharmaceuticals, Inc. (INDV) invested $97.0M in research and development during fiscal year 2025.
Indivior Pharmaceuticals, Inc. (INDV) had a current ratio of 0.71 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Indivior Pharmaceuticals, Inc. (INDV) had a return on assets of 17.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, Indivior Pharmaceuticals, Inc. (INDV) held $223.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.0M over that year. Dividing the one by the other, the reported balance equals about 99 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Indivior Pharmaceuticals, Inc. (INDV) has negative shareholder equity of -$98.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Indivior Pharmaceuticals, Inc. (INDV) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
For every $1 of reported earnings, Indivior Pharmaceuticals, Inc. (INDV) used $0.13 of operating cash (-$27.0M OCF vs $210.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Indivior Pharmaceuticals, Inc. (INDV) has an interest coverage ratio of 6.89x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Indivior Pharmaceuticals, Inc. (INDV) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.